@article {Roy884, author = {Jean-Nicholas Roy and Julie Lajoie and Lynn S. Zijenah and Azemi Barama and Charles Poirier and Brian J. Ward and Michel Roger}, title = {CYP3A5 GENETIC POLYMORPHISMS IN DIFFERENT ETHNIC POPULATIONS}, volume = {33}, number = {7}, pages = {884--887}, year = {2005}, doi = {10.1124/dmd.105.003822}, publisher = {American Society for Pharmacology and Experimental Therapeutics}, abstract = {Cyp3A5 activity varies within any given ethnic population, suggesting that genetic variation within the Cyp3A5 gene may be the most important contributor to interindividual and interracial differences in Cyp3A-dependent drug clearance and response. The full extent of Cyp3A5 polymorphism in a white and an indigenous African population was analyzed using DNA direct sequencing procedures. The presence of 10 and 12 single nucleotide polymorphisms was detected in the white and African samples, respectively. Thirteen novel mutations occurring at low frequencies were identified in these populations. Significant differences were observed in the distribution of Cyp3A5*3, Cyp3A5*6, and Cyp3A5*7 alleles among white and African populations. The frequency of Cyp3A5*3 allele in white Canadians (\~{}93\%) is higher than in Zimbabweans (77.6\%) (p \< 0.001). In contrast, Cyp3A5*6 and Cyp3A5*7 alleles are relatively frequent in African subjects (10{\textendash}22\%) but absent in white subjects (p \< 0.001). These differences may reflect evolutionary pressures generated by environmental factors in geographically distinct regions. However, the genetic polymorphism of Cyp3A5 alone does not explain the interindividual differences in Cyp3A-mediated metabolism. The American Society for Pharmacology and Experimental Therapeutics}, issn = {0090-9556}, URL = {https://dmd.aspetjournals.org/content/33/7/884}, eprint = {https://dmd.aspetjournals.org/content/33/7/884.full.pdf}, journal = {Drug Metabolism and Disposition} }